Update on Rotarix™: an oral human rotavirus vaccine

References

• WHO. Rotavirus vaccines. Wkly Epidemiol. Rec.82, 285–295 (2007).
   PubMedGoogle Scholar
• Parashar UD, Burton A, Lanata C et al. Global mortality associated with rotavirus disease among children in 2004. J. Infect. Dis.200(Suppl. 1), S9–S15 (2009).
   PubMed Web of Science ®Google Scholar
• Parashar UD, Hummelman EG, Bresee JS, Miller MA, Glass RI. Global illness and deaths caused by rotavirus disease in children. Emerg. Infect. Dis.9, 565–572 (2003).
   PubMed Web of Science ®Google Scholar
• Parashar UD, Gibson CJ, Bresse JS, Glass RI. Rotavirus and severe childhood diarrhea. Emerg. Infect. Dis.12, 304–306 (2006).
   PubMed Web of Science ®Google Scholar
• Glass RI, Bresee JS, Turcios R, Fischer TK, Parashar UD, Steele AD. Rotavirus vaccines: targeting the developing world. J. Infect. Dis.192, S160–S166 (2005).
   PubMed Web of Science ®Google Scholar
• de Oliveira LH, Danovaro-Holliday MC, Matus CR, Andrus JK. Rotavirus vaccine introduction in the Americas: progress and lessons learned. Expert Rev. Vaccines7(3), 345–353 (2008).
   PubMed Web of Science ®Google Scholar
• Abate H, Linhares AC, Venegas G et al. Results of a hospital-based study on rotavirus gastroenteritis in Latin American children. Presented at: 24th International Congress of Pediatrics (ICP). Cancun, Mexico, 15–20 August 2004 (Abstract 656).
   Google Scholar
• O’Ryan M, Pérez-Schael I, Mamani N et al. Rotavirus-associated medical visits and hospitalizations in South America: a prospective study at three large sentinel hospitals. Pediatr. Infect. Dis. J.20, 685–693 (2001).
   PubMed Web of Science ®Google Scholar
• Rheingans RD, Constenla D, Antill L, Innis BL, Breuer T. Economic and health burden of rotavirus gastroenteritis from 2003 birth cohort in eight Latin American and Caribbean countries. Rev. Panam. Salud. Publica21, 192–204 (2007).
   PubMed Web of Science ®Google Scholar
• Lepage P. Rotavirus infection in Europe. Time for effective prevention. Pediatr. Infect. Dis. J.25(1 Suppl.), S5–S6 (2006).
   PubMed Web of Science ®Google Scholar
• Soriano-Gabarro M, Mrukowicz J, Vesikari T, Verstraeten T. Burden of rotavirus disease in European Union countries. Pediatr. Infect. Dis.25, 7–11 (2006).
   Google Scholar
• Tucker AW, Haddix AC, Bresee JS, Holman RC, Parashar UD, Glass RI. Cost–effectiveness analysis of a rotavirus immunization program for the United States. JAMA279, 1371–1376 (1998).
   PubMed Web of Science ®Google Scholar
• Parashar UD, Holman RC, Clarke MJ, Bresee JS, Glass RI. Hospitalizations associated with rotavirus diarrhoea in the United States, 1993 through 1995: surveillance based on the new ICD-9-CM rotavirus-specific diagnostic code. J. Infect. Dis.177, 13–17 (1997).
   Web of Science ®Google Scholar
• Charles MD, Holman RC, Curns AT, Parashar UD, Glass RI, Bresee JS. Hospitalizations associated with rotavirus gastroenteritis in the United States, 1993–2002. Pediatr. Infect. Dis. J.25, 489–493 (2006).
   PubMed Web of Science ®Google Scholar
• Malek MA, Curns AT, Holman RC et al. Diarrhoea- and rotavirus-associated hospitalizations among children less than 5 years of age: United States, 1997 and 2000. Pediatrics117, 1887–1892 (2006).
   PubMed Web of Science ®Google Scholar
• Parashar UD, Glass RI. Rotavirus vaccines – early success, remaining questions. N. Engl. J. Med.360, 1063–1065 (2009).
   PubMed Web of Science ®Google Scholar
• Widdowson M-A, Meltzer MI, Zhang X, Bresee JS, Parashar UD, Glass RI. Cost–effectiveness and potential impact of rotavirus vaccination in the United States. Pediatrics119, 684–697 (2007).
   PubMed Web of Science ®Google Scholar
• CDC. Delayed onset and diminished magnitude of rotavirus activity – United States, November 2007–May 2008. MMWR Morb. Mortal. Wkly Rep.57, 697–700 (2008).
   PubMedGoogle Scholar
• Staat MA, Azimi PH, Berke T et al. Clinical presentations of rotavirus infection among hospitalised children. Pediatr. Infect. Dis.21, 221–227 (2002).
   Google Scholar
• Parashar UD, Glass RI. Rotavirus vaccination in Europe: the time has finally arrived. J. Pediatr. Gastroenterol. Nutr.46, S21–S23 (2008).
   Web of Science ®Google Scholar
• Standaert B, Harlin O, Desselberger U. The financial burden of rotavirus disease in four countries of the European Union. Pediatr. Infect. Dis. J.27, 20–27 (2008).
   Web of Science ®Google Scholar
• WHO. Evaluating clinical trials data and guiding future research for rotavirus vaccines. Wkly Epidemiol. Rec.83, 385–388 (2008).
   PubMedGoogle Scholar
• Kosek M, Bern C, Guerrant RL. The global burden of diarrhoeal disease, as estimated from studies published between 1992 and 2000. Bull. World Health Organ.81, 197–204 (2003).
   PubMed Web of Science ®Google Scholar
• Bernstein DI. Rotavirus overview. Pediatr. Infect. Dis. J.28(3 Suppl.), S50–S53 (2009).
   PubMed Web of Science ®Google Scholar
• WHO. Rotavirus vaccines, an update. Wkly Epidemiol. Rec.78, 2–3 (2003).
   PubMedGoogle Scholar
• Glass RI, Parashar UD, Bresee JS et al. Rotavirus vaccines: current prospects and future challenges. Lancet368, 323–332 (2006).
   PubMed Web of Science ®Google Scholar
• Estes MK, Kapikian AZ. Rotaviruses. In: Fields Virology (5th Edition). Knipe DM, Howley PM (Eds). Lippincott Williams & Wilkins, PA, USA, 1917–1974 (2007).
   Google Scholar
• Hoshino Y, Kapikian AZ. Rotavirus serotypes: classification and importance in epidemiology, immunity and vaccine development. J. Health Popul. Nutr.18, 5–14 (2000).
   PubMed Web of Science ®Google Scholar
• O’Ryan M. The ever-changing landscape of rotavirus serotypes. Pediatr. Infect. Dis. J.28, S60–S62 (2009).
   PubMed Web of Science ®Google Scholar
• Santos N, Hoshino Y. Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine. Rev. Med. Virol.5, 29–56 (2005).
   Web of Science ®Google Scholar
• Ward R. Mechanisms of protection against rotavirus infection and disease. Pediatr. Infect. Dis. J.28, S57–S59 (2009).
   Web of Science ®Google Scholar
• Franco MA, Angel J, Greenberg HB. Immunity and correlates of protection for rotavirus vaccines. Vaccine24, 2718–2731 (2006).
   PubMed Web of Science ®Google Scholar
• Bishop RF, Barnes GL, Cipriani E et al. Clinical immunity after neonatal rotavirus infection. A prospective longitudinal study in young children. N. Engl. J. Med.309, 72–76 (1983).
   PubMed Web of Science ®Google Scholar
• Velazquez FR, Matson DO, Calva JJ et al. Rotavirus infection in infants as protection against subsequent infections. N. Engl. J. Med.335, 1022–1028 (1996).
   PubMed Web of Science ®Google Scholar
• Green KY, Taniguchi K, McKow ER, Kapikian AZ. Homotypic and heterotypic epitope-specific antibody responses in adult and infant rotavirus vaccines: implications for vaccine development. J. Infect. Dis.16, 667–679 (1990).
   Google Scholar
• Ward RL, Clemens JD, Knowlton DR et al. Evidence that protection against rotavirus diarrhea after natural infection is not dependent on serotype-specific neutralizing antibody. J. Infect. Dis.166, 1251–1257 (1992).
   PubMed Web of Science ®Google Scholar
• Gray J, Vesikari T, Van Damme P et al. Rotavirus. J. Pediatr. Gastroenterol. Nutr.46, 24–31 (2008).
   PubMed Web of Science ®Google Scholar
• CDC. Intusssusception among recipients of rotavirus vaccine – United States, 1998–1999. MMWR Morb. Mortal. Wkly Rep.27, 577–581 (1999).
   Google Scholar
• CDC. Withdrawal of rotavirus vaccine recommendation. MMWR Morb. Mortal. Wkly Rep.48, 1007 (1999).
   PubMedGoogle Scholar
• Peter G, Myers MG. Intussusception, rotavirus, and oral vaccines: summary of a workshop. Pediatrics110, e7 (2002).
   PubMedGoogle Scholar
• WHO. Global Advisory Committee on Vaccine Safety Report. Wkly Epidemiol. Rec.2, 15–19 (2006).
   Google Scholar
• Bines JE. Rotavirus vaccines and intussusception risk. Curr. Opin. Gastroenterol.21, 20–25 (2005).
   PubMed Web of Science ®Google Scholar
• Ruiz-Palacios G, Pérez-Schael I, Velázquez RF et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N. Engl. J. Med.354, 11–22 (2006).
   PubMed Web of Science ®Google Scholar
• Vesikari T, Matson DO, Dennehy P et al. Safety and efficacy of a pentavalent human–bovine (WC3) reassortant rotavirus vaccine. N. Engl. J. Med.354, 23–33 (2006).
   PubMed Web of Science ®Google Scholar
• Vesikari T, Karvonen A, Prymula R et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind, placebo-controlled study. Lancet370, 1757–1763 (2007).
   PubMed Web of Science ®Google Scholar
• Vesikari T, Itzler R, Matson DO et al. Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated healthcare utilization across 3 regions (11 countries). Int. J. Infect. Dis.11(Suppl. 2), S29–S35 (2007).
   PubMed Web of Science ®Google Scholar
• Patel M, Pedreira C, de Oliveira LH et al. Association between pentavalent rotavirus vaccine and severe rotavirus diarrhea among children in Nicaragua. JAMA301, 2243–2251 (2009).
   PubMed Web of Science ®Google Scholar
• Block SL, Vesikari T, Goveia MG et al. Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life. Pediatrics119, 11–18 (2007).
   PubMed Web of Science ®Google Scholar
• Vesikari T, Karvonen A, Ferrante SA, Lawrence J, Ciarlet M. Efficacy of the pentavalent rotavirus vaccine, RotaTeq™, against hospitalisations and emergency department visits up to 3 years post-vaccination: the Finnish extension study. Presented at: 13th International Congress on Infectious Diseases. Kuala Lumpur, Malaysia, 19–22 June 2008 (Abstract 19.025).
   Google Scholar
• Staat MA, Fairbrother G, Edwards KM et al. Delayed onset and diminished magnitude of rotavirus activity – United States, November 2007–May 2008. MMWR Morb. Mortal. Wkly Rep.57, 697–700 (2008).
   PubMedGoogle Scholar
• Fu C, Wang M, Liang J, He T, Wang D, Xu J. Effectiveness of Lanzhou lamb rotavirus vaccine against rotavirus gastroenteritis requiring hospitalization: a matched case–control study. Vaccine25, 8756–8761 (2007).
   PubMed Web of Science ®Google Scholar
• Vesikari T, Karvonen AV, Majuri J et al. Safety, efficacy and immunogenicity of 2 doses of bovine–human (UK) and rhesus–human rotavirus reassortant tetravalent vaccines in Finnish children. J. Infect. Dis.194, 370–376 (2006).
   PubMed Web of Science ®Google Scholar
• Bandhari N, Sharma P, Glass RI et al. Safety and immunogenicity of two live attenuated human rotavirus vaccine candidates, 116E and I1321, in infants: results of a randomized controlled trial. Vaccine24, 5817–5823 (2006).
   PubMed Web of Science ®Google Scholar
• Barnes GL, Lund JS, Mitchell SV et al. Early Phase II trial of human rotavirus vaccine candidate RV3. Vaccine20, 2950–2956 (2002).
   PubMed Web of Science ®Google Scholar
• Ward RL, McNeal MM, Steele AD. Why does the world need another rotavirus vaccine? Ther. Clin. Risk Manag.4, 49–63 (2008).
   PubMedGoogle Scholar
• Bernstein DI, Ward RL. Rotarix: development of a live attenuated monovalent human rotavirus vaccine. Pediatr. Ann.35, 38–43 (2006).
   PubMed Web of Science ®Google Scholar
• Bernstein DI, Smith VE, Sherwood JR et al. Safety and immunogenicity of live, attenuated human rotavirus vaccine 89–12. Vaccine16(4), 381–387 (1998).
   PubMed Web of Science ®Google Scholar
• De Vos B, Vesikari T, Linhares AC et al. A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis. Pediatr. Infect. Dis. J.23(10 Suppl.), S179–S182 (2004).
   PubMed Web of Science ®Google Scholar
• Nakagomi T, Nakagomi O. A critical review on a globally-licensed, live, orally-administrable, monovalent human rotavirus vaccine: Rotarix. Expert Opin. Biol. Ther.9, 1073–1086 (2009).
   PubMed Web of Science ®Google Scholar
• O’Ryan M. Rotarix™ (RIX4414): an oral human rotavirus vaccine. Expert Rev. Vaccines6, 11–19 (2007).
   PubMed Web of Science ®Google Scholar
• Vesikari T, Karvonen A, Korhonen T et al. Safety and immunogenicity of RIX4414 live attenuated human rotavirus vaccine in adults, toddlers and previously uninfected infants. Vaccine22, 2836–2842 (2004).
   PubMed Web of Science ®Google Scholar
• Bernstein DI, Sack DA, Rothstein E et al. Efficacy of live, attenuated, human rotavirus vaccine 89–12 in infants: a randomized placebo-controlled trial. Lancet354, 287–290 (1999).
   PubMed Web of Science ®Google Scholar
• Bernstein DI, Sack DI, Reisinger K, Rothstein E, Ward R. Second-year follow-up evaluation of live, attenuated human rotavirus vaccine 89–12 in healthy infants. J. Infect. Dis.186, 1487–1489 (2002).
   PubMed Web of Science ®Google Scholar
• Dennehy PH, Brady RC, Halperin SA et al.; North American Human Rotavirus Vaccine Study Group. Comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccine. Pediatr. Infect. Dis. J.24, 481–488 (2005).
   PubMed Web of Science ®Google Scholar
• Vesikari T, Karvonen A, Puustinen L et al. Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants. Pediatr. Infect. Dis. J.23(10), 937–943 (2004).
   PubMed Web of Science ®Google Scholar
• Salinas B, Pérez Schael I, Linhares A et al. Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414. Pediatr. Infect. Dis. J.24(9), 807–816 (2005).
   PubMed Web of Science ®Google Scholar
• Phua KB, Quak SH, Lee BW et al. Evaluation of RIX4414, a live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled Phase 2 trial involving 2464 Singaporean infants. J. Infect. Dis.192, S6–S16 (2005).
   PubMed Web of Science ®Google Scholar
• Cheuvart B, Friedland LR, Abu-Elyazeed R, Han HH, Guerra Y, Verstraeten T. The human rotavirus vaccine RIX4414 in infants. A review of safety and tolerability. Pediatr. Infect. Dis. J.28, 225–232 (2009).
   PubMed Web of Science ®Google Scholar
• López P, Linhares A, Pérez-Schael I et al. Early protection against severe rotavirus gastroenteritis – RIX4414 experience in Latin America. Presented at: 24th Annual Meeting of the European Society for Pediatric Infectious Diseases –ESPID. Basel, Switzerland, 3–5 May 2006.
   Google Scholar
• Vesikari T, Prymula R, Schuster V et al. Early protection against rotavirus, Rotarix™ (RIX4414) experience in a European setting. Int. J. Infect. Dis.10(Suppl. 1), Abstract 68.021 (2006).
   Google Scholar
• Steele A, Tumbo J, Armah G et al. Concomitant administration of a live-attenuated oral rotavirus vaccine (RIX4414) with poliovirus vaccines in African infants. Presented at: 23rd Annual Meeting of the European Society for Pediatric Infectious Diseases – ESPID. Valencia, Spain, 18–20 May 2005.
   Google Scholar
• Steele AD, De Vos B, Tumbo J et al. Co-administration study in South African infants of a live-attenuated oral human rotavirus vaccine (RIX4414) and poliovirus vaccines. Vaccine (2009) (Epub ahead of print).
   Google Scholar
• Lopez P, Abate HJ, De Leon T et al. Immunogenicity of an oral polio vaccine is unaffected when co-administered with a human vaccine RIX4414 (Rotarix™) in Latin America. Presented at: 13th International Congress on Infectious Diseases. Kuala Lumpur, Malaysia, 19–22 June 2008 (Abstract no. 19.029).
   Google Scholar
• Tregnaghi M, Lopez P, De Leon T et al. Oral human rotavirus vaccine RIX4414 (Rotarix™ 19.02) co-administered with routine EPI vaccinations including oral poliovirus vaccine (OPV) is highly efficacious in Latin America. Presented at: 13th International Congress on Infectious Diseases. Kuala Lumpur, Malaysia, 19–22 June 2008 (Abstract no. 19.020).
   Google Scholar
• Linhares AC, Velázquez FR, Pérez-Schael I et al. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled Phase III study. Lancet371, 1181–1189 (2008).
   PubMed Web of Science ®Google Scholar
• Phua KB, Lim FS, Lau YL et al. Human rotavirus vaccine RIX4414 (Rotarix™) is highly efficacious in infants from Asia during the first two years of life. Presented at: 13th International Congress on Infectious Diseases. Kuala Lumpur, Malaysia, 19–22 June 2008 (Abstract no. 19.024).
   Google Scholar
• Phua KB, Lim FS, Lau YL et al. Human rotavirus vaccine RIX4414 is highly efficacious in Asian infants during the third year of life. Presented at: 26th Annual Meeting of the European Society of Paediatric Infectious Diseases. Brussels, Belgium, 9–13 June 2009.
   Google Scholar
• Cunliffe K, Kirsten M, Madhi S et al. Efficacy of human rotavirus vaccine RIX4414 in Africa during the first year of life. Presented at: 26th Annual Meeting of the European Society of Paediatric Infectious Diseases. Brussels, Belgium, 9–13 June 2009 (Abstract no. 572).
   Google Scholar
• Pérez-Schael I, Salinas B, Tomat M et al. Efficacy of the human rotavirus vaccine RIX4414 in malnourished children. J. Infect. Dis.196, 537–540 (2007).
   PubMed Web of Science ®Google Scholar
• Omenñaca F, Sarlangue J, Wisocki J et al. Immunogenicity of rotavirus vaccine (RIX4414) in European pre-term infants with different gestational age. Presented at: 26th Annual Meeting of the European Society of Paediatric Infectious Diseases. Brussels, Belgium, 9–13 June 2009.
   Google Scholar
• Gurgel RQ, Cuevas LE, Vieira SCF et al. Predominance of rotavirus P[4]G2 in a vaccinated population, Brazil. Emerg. Infect. Dis.13, 1571–1573 (2007).
   PubMed Web of Science ®Google Scholar
• Nakagomi T, Cuevas LE, Gurgel RG et al. Apparent extinction of non-G2 rotavirus strains from circulation in Recife, Brazil, after the introduction of rotavirus vaccine. Arch. Virol.153, 591–593 (2008).
   PubMed Web of Science ®Google Scholar
• Patel MM, de Oliveira LH, Bispo AM, Gentsch J, Parashar UD. Rotavirus P[4]G2 in a vaccinated population, Brazil. Emerg. Infect. Dis.14, 8635 (2008).
   Google Scholar
• Nakagomi T, Patel M, Nakagomi O et al. Effectiveness of monovalent G1P[8] vaccine, Rotarix, in Recife, Brazil, against severe diarrhoea caused by G2P[4] rotavirus strains. Presented at: 26th Annual Meeting of the European Society of Paediatric Infectious Diseases. Brussels, Belgium, 9–13 June 2009.
   Google Scholar
• Isakbaeva ET, Musabaev E, Antil L et al. Rotavirus disease in Uzbekistan: cost–effectiveness of a new vaccine. Vaccine25, 373–380 (2007).
   PubMed Web of Science ®Google Scholar
• Fischer TK, Anh DD, Antil L et al. Healthcare costs of diarrheal disease and estimates of the cost–effectiveness of rotavirus vaccination in Vietnam. J. Infect. Dis.192(10), 1720–1726 (2005).
   PubMed Web of Science ®Google Scholar
• Constenla D, O’Ryan M, Navarrete MS, Antil L, Reinghan R. Evaluación de costo–efectividad de la vacuna anti-rotavirus en Chile. Rev. Med. Chile134(6), 679–688 (2006).
   PubMed Web of Science ®Google Scholar
• Fruytier A, Van Schoor J, Standaert B. Vaccination with RIX4414 is cost-effective in a Belgian setting. Presented at: International Society for Pharmacoeconomics and Outcomes Research 9th Annual European Congress. Copenhagen, Denmark, 28–31 October 2006.
   Google Scholar
• Melliez H, Levybrhl D, Boelle PY, Dervaux B, Baron S, Yazdanpanah Y. Cost and cost–effectiveness of childhood vaccination against rotavirus in France. Vaccine26, 706–715 (2008).
   PubMed Web of Science ®Google Scholar
• Jit M, Edmunds WJ. Evaluating rotavirus vaccination in England and Wales. Part II: the potential cost–effectiveness of vaccination. Vaccine25, 3971–3979 (2007).
   PubMed Web of Science ®Google Scholar
• Newall AT, Beutels P, Macartney K, Wood J, MacIntyre CR. The cost–effectiveness of rotavirus vaccination in Australia. Vaccine25, 8851–8860 (2007).
   PubMed Web of Science ®Google Scholar
• de Soarez PC, Castelo A, Abrão P, Holmes WC, Ciconelli RM. Cost–effectiveness analysis of routine rotavirus vaccination in Brazil. Rev. Panam. Salud Publica23, 221–230 (2008).
   PubMed Web of Science ®Google Scholar
• Constenla DO, Linhares AC, Rheingans RD, Antil LR, Waldman EA, da Silva LJ. Economic impacto of a rotavirus vaccine in Brazil. J. Health Popul. Nutr.26, 388–396 (2008).
   PubMed Web of Science ®Google Scholar
• Rheingans RD, Constenla D, Antil L, Innis BL, Breuer T. Potential cost–effectiveness of vaccination for rotavirus gastroenteritis in eight Latin American and Caribbean countries. Rev. Panam. Salud Publica21, 205–216 (2008).
   Web of Science ®Google Scholar
• McCormack PL, Kean SJ, Bernstein DI et al. Rotavirus vaccine RIX4414 (Rotarix™). A review of its use in the prevention of rotavirus gastroenteritis. Pediatr. Drugs11, 75–88 (2009).
   PubMedGoogle Scholar
• WHO. Meeting of the Diarrhoeal and Enteric Vaccines Advisory Committee, October 2008 – executive summary. Rotavirus. Wkly Epidemiol. Rec.84, 32–34 (2009).
   Google Scholar
• WHO. Global Advisory Committee on Vaccine Safety, report of meeting held 17–18 June 2009. Wkly Epidemiol. Rec.32, 327–328 (2009).
   Google Scholar
• Rivera L. Transmission of the human rotavirus vaccine RIX4414 between twins. Presented at: 10th International Symposium on Double-Stranded RNA Viruses. Hamilton Island, Great Barrier Reef, Australia, 21–25 June 2009 (Abstract 045).
   Google Scholar